Marshall Wace
AUTL

Marshall Wace’s Autolus Therapeutics AUTL Stock Holding History

Marshall Wace’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151K Buy
94,654
+67,972
+255% +$107K ﹤0.01% 2872
2026
Q1 		$36.8K Sell
26,682
-243,595
-90% -$370K ﹤0.01% 3006
2025
Q4 		$538K Sell
270,277
-371,675
-58% -$571K ﹤0.01% 2209
2025
Q3 		$1.05M Buy
+641,952
New +$1.25M ﹤0.01% 1923
2025
Q2 		– Sell
-619,913
Closed -$961K – 2694
2025
Q1 		$961K Sell
619,913
-137,622
-18% -$279K ﹤0.01% 1797
2024
Q4 		$1.78M Hold
757,535
– – ﹤0.01% 1494
2024
Q3 		$2.75M Hold
757,535
– – ﹤0.01% 1241
2024
Q2 		$2.64M Sell
757,535
-282,142
-27% -$1.22M ﹤0.01% 1243
2024
Q1 		$6.63M Buy
1,039,677
+542,724
+109% +$3.39M 0.01% 884
2023
Q4 		$3.2M Buy
+496,953
New +$1.9M 0.01% 1060
2023
Q3 		– Sell
-25,496
Closed -$60.7K – 2179
2023
Q2 		$60.7K Buy
+25,496
New +$60.5K ﹤0.01% 2364
2022
Q1 		– Sell
-16,178
Closed -$85K – 3337
2021
Q4 		$85K Buy
+16,178
New +$97.1K ﹤0.01% 3420
2021
Q3 		– Sell
-297,749
Closed -$1.98M – 3008
2021
Q2 		$1.98M Buy
297,749
+198,736
+201% +$1.23M 0.01% 1427
2021
Q1 		$568K Buy
+99,013
New +$733K ﹤0.01% 1894
2020
Q3 		– Sell
-13,672
Closed -$220K – 1562
2020
Q2 		$220K Sell
13,672
-471,557
-97% -$5.23M ﹤0.01% 1393
2020
Q1 		$2.91M Sell
485,229
-194,952
-29% -$1.8M 0.03% 509
2019
Q4 		$8.98M Buy
680,181
+173,174
+34% +$2.27M 0.06% 336
2019
Q3 		$6.3M Sell
507,007
-8,398
-2% -$111K 0.05% 427
2019
Q2 		$8.3M Buy
515,405
+282,474
+121% +$6.32M 0.07% 337
2019
Q1 		$7.33M Buy
232,931
+112,489
+93% +$3.2M 0.07% 342
2018
Q4 		$3.96M Buy
+120,442
New +$3.96M 0.04% 521

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace's AUTL Position: Q2 2026 in Review

Marshall Wace increased its Autolus Therapeutics (AUTL) stake by 255% in Q2 2026, buying an estimated $107K and bringing the position to 94,654 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

Marshall Wace first reported a position in AUTL in Q4 2018 and has held it in 21 quarters since. The position peaked at $8.98M in Q4 2019. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Marshall Wace held 94,654 shares of Autolus Therapeutics worth $151K as of Q2 2026.
  • Marshall Wace bought 67,972 Autolus Therapeutics shares in Q2 2026, an estimated $107K.
  • Autolus Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2872 holding.
  • Marshall Wace first reported a position in Autolus Therapeutics in Q4 2018 and has held it in 21 quarters since.
  • Marshall Wace's Autolus Therapeutics position peaked at $8.98M in Q4 2019.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.